BBIQ 是一种咪唑喹啉化合物，是一种有效且选择性的 toll 样受体 7 (TLR7) 激动剂，对人 TLR7 的 EC50 为 59.1 nM。BBIQ 还是一种功能强大的疫苗佐剂，可增强机体的先天免疫应答。

BBIQ is a powerful vaccine adjuvant that enhances innate immune responses and it is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7.

BBIQ induces IFN-α in human PBMCs (520 pg/mL at 5 μg/mL)[1].

In mice treated with Chloroquine (CQ) alone, parasite (P. berghei ANKA) appearesd on Day 17 and all mice of this group died by Day 21. Mice treated with BBIQ along with CQ exhibits no appearance of parasite till Day 23. Frequencies of T cells (CD3+, CD4+and CD8+) and T regulatory cells (CD4+, CD25 +and FoxP3+) are lower in brain of BBIQ + CQ treated mice as compared to BBIQ alone and CQ alone treated mice on Day 10. Serum levels of IFN-γ and IL-12 are higher on same day in mice treated with BBIQ + CQ which reveals the generation of strong Th1 immune response in mice against the infection[1]. Inhibition of infiltration of inflammatory T cells and activation of T helper and T cytotoxic cells against the parasite is observed in the mice treated with this combination therapy.

1229024-57-0

C21H22N4

330.43

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years